You are here

Medical Product Safety

Expand All Objectives

Baseline: 60.7 percent of medical-surgical hospitals reported adverse drug events in 2009
Target: 66.8 percent
Target-Setting Method: 10 percent improvement
Data Sources:
National Survey of Pharmacy Practice in Hospital Care Settings, American Society of Health-System Pharmacists (ASHP)
Data:
Data for this objective HP2020 data for this objective
Data Details Details about the methodology and measurement of this HP2020 objective
Healthy People 2010 The HP2010 objective with the same definition was 17-01a.
Search data for all HP2010 objectives
Revision History: This objective was revised. Read more about the revision history.
More Information:
MPS-2 Increase the safe and effective treatment of pain
MPS-2.1 (Developmental) Reduce the proportion of patients suffering from untreated pain due to a lack of access to pain treatment
Archived

This objective was archived due to lack of data source, changes in science, or was replaced with other objectives. See Revision History for Details.

Potential Data Sources:
Medical Expenditure Panel Survey (MEPS), AHRQ
Revision History: This objective was archived due to lack of a viable data source. Read more about the revision history.
More Information:
MPS-2.2 Reduce the number of non-FDA-approved pain medications
Archived

This objective was archived due to lack of data source, changes in science, or was replaced with other objectives. See Revision History for Details.

Baseline: 575 non-FDA-approved pain medications (opioids, nonsteroidal anti-inflammatory drugs [NSAIDs], and acetaminophen used to treat pain) were on the market in 1 year beginning January 2007
Target: 518 non-FDA-approved pain medications
Target-Setting Method: 10 percent improvement
Potential Data Sources:
FDA Drug Registration and Listing Database, FDA; Electronic database of prescription sales in the US, Intercontinental Marketing Services (IMS)
Data:
Data for this objective HP2020 data for this objective
Data Details Details about the methodology and measurement of this HP2020 objective
Revision History: This objective was archived due to a change in policy. Read more about the revision history.
More Information:
MPS-2.3 (Developmental) Reduce serious injuries from the use of pain medicines
Archived

This objective was archived due to lack of data source, changes in science, or was replaced with other objectives. See Revision History for Details.

Potential Data Sources:
Adverse Event Reporting System (AERS), FDA
Revision History: This objective was archived due to lack of a viable data source. Read more about the revision history.
More Information:
Potential Data Sources:
Adverse Event Reporting System (AERS), FDA
More Information:
MPS-3 (Developmental) Reduce the number of adverse events from medical products
Archived

This objective was archived due to lack of data source, changes in science, or was replaced with other objectives. See Revision History for Details.

Potential Data Sources:
National Electronic Injury Surveillance System (NEISS), CPSC
Revision History: This objective was archived due to lack of a viable data source. Read more about the revision history.
More Information:
Baseline: 15 safe and effective medical products were associated with predictive biomarkers through 2010
Target: Not applicable
Target-Setting Method: This measure is being tracked for informational purposes. If warranted, a target will be set during the decade.
Data Sources:
Drugs@FDA, FDA/CDER and FDA/CBER; List of Cleared and Approved Companion Diagnostic Devices (In Vivo and Imaging tools), FDA/CDRH; Releasable Pre-Market Approval (PMA) database, FDA/CDRH
Data:
Data for this objective HP2020 data for this objective
Data Details Details about the methodology and measurement of this HP2020 objective
Revision History: This objective was revised. Read more about the revision history.
More Information:
MPS-5 Reduce emergency department (ED) visits for common, preventable adverse events from medications
Baseline: 35.9 ED visits per 10,000 outpatient prescription visits for overdoses from oral anticoagulants occurred in 2006–07
Target: 32.3 ED visits per 10,000 outpatient prescription visits
Target-Setting Method: 10 percent improvement
Data Sources:
National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES), CDC and CPSC and FDA; National Ambulatory Medical Care Survey (NAMCS), CDC/NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), C
Data:
Data for this objective HP2020 data for this objective
Data for this objective Spotlight on Disparities:
Data Details Details about the methodology and measurement of this HP2020 objective
Revision History: This objective was revised. Read more about the revision history.
More Information:
Baseline: 43.4 ED visits per 10,000 outpatient prescription visits for overdoses from injectable antidiabetic agents occurred in 2006–07
Target: 39.1 ED visits per 10,000 outpatient prescription visits
Target-Setting Method: 10 percent improvement
Data Sources:
National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES), CDC and CPSC and FDA; National Ambulatory Medical Care Survey (NAMCS), CDC/NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), C
Data:
Data for this objective HP2020 data for this objective
Data for this objective Spotlight on Disparities:
Data Details Details about the methodology and measurement of this HP2020 objective
Revision History: This objective was revised. Read more about the revision history.
More Information:
Baseline: 8.9 ED visits per 10,000 outpatient prescription visits for overdoses from narrow-therapeutic-index medications occurred in 2006–07
Target: 8.0 ED visits per 10,000 outpatient prescription visits
Target-Setting Method: 10 percent improvement
Data Sources:
National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES), CDC and CPSC and FDA; National Ambulatory Medical Care Survey (NAMCS), CDC/NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), C
Data:
Data for this objective HP2020 data for this objective
Data for this objective Spotlight on Disparities:
Data Details Details about the methodology and measurement of this HP2020 objective
Revision History: This objective was revised. Read more about the revision history.
More Information:
Baseline: 32.7 ED visits per 10,000 children less than 5 years of age occurred in 2007–08
Target: 29.4 ED visits per 10,000 children less than 5 years of age
Target-Setting Method: 10 percent improvement
Data Sources:
National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES), CDC and CPSC and FDA; Bridged-Race Population Estimates, CDC/NCHS and Census
Data:
Data for this objective HP2020 data for this objective
Data for this objective Spotlight on Disparities:
Data Details Details about the methodology and measurement of this HP2020 objective
Revision History: This objective was revised. Read more about the revision history.
More Information: